Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,139.00    0.00 (0.00%)
Bid:
1,060.00
Ask:
0.00
Spread: 81.50 (7.689%)
Market Cap: £9.67b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Pre Stabilisation Notice

27 May 2026 09:31

RNS Number : 8736F
HSBC Bank plc
27 May 2026
 

27th May 2026

 

Smith & Nephew plc

Pre Stabilisation Notice

HSBC (contact: syndexecution@noexternalmail.hsbc.com) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities

The securities:

Issuer:

Smith & Nephew plc

Guarantor (if any):

n/a

Aggregate nominal amount:

EUR Benchmark

Description:

Fixed rate 12yr due 3rd Jun 2038

Offer price:

TBC

Other offer terms:

Stabilisation:

Stabilising Manager(s):

HSBC Bank plc

Stabilisation period expected to start on:

27th May 2026

Stabilisation period expected to end no later than:

3rd July 2026

Existence, maximum size & conditions of use of over-allotment facility[1]:

5% of the aggregate nominal amount

Stabilisation Venue(s)

Over the counter (OTC)

 

In connection with the offer of the above securities, the Stabilisation Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilisation Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time. Any stabilisation action or over-allotment shall be conducted in accordance with all applicable laws and rules.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Regulation (EU) 2017/1129 (the "Prospectus Regulation") (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Regulation), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Regulation (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.


[1] Please note that the existence and the maximum size of any greenshoe option, the exercise period of the greenshoe option and any conditions for exercise of the greenshoe option must also be disclosed, if such option exists. In addition, the exercise of the greenshoe option must be disclosed to the public promptly, together with all appropriate details, including in particular the date of exercise and the number and nature of securities involved 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STAZZGZKRNRGVZG
Date   Source Headline
11th May 20212:32 pmRNSHolding(s) in Company
4th May 202112:38 pmRNSTotal Voting Rights
4th May 20219:45 amRNSDirector/PDMR Shareholding
29th Apr 20217:00 amRNSTrading Statement
28th Apr 20217:00 amRNSDividend Declaration
14th Apr 20216:04 pmRNSResult of AGM
1st Apr 20211:15 pmRNSTotal Voting Rights
1st Apr 20219:00 amRNSDirector Declaration
31st Mar 202110:00 amRNSAdditional Annual General Meeting update
19th Mar 20211:00 pmRNSDirector/PDMR Shareholding
19th Mar 20219:00 amRNSNotice of Results
17th Mar 20213:30 pmRNSDirector/PDMR Shareholding
10th Mar 20215:45 pmRNSDirector/PDMR Shareholding
9th Mar 20215:48 pmRNSDirector/PDMR Shareholding
8th Mar 202111:30 amRNSDirector/PDMR Shareholding
1st Mar 20214:18 pmRNSAnnual Financial Report
1st Mar 20211:00 pmRNSTotal Voting Rights
18th Feb 20217:00 amRNSFourth Quarter and Full Year 2020 Results
11th Feb 20217:00 amRNSDirector Declaration
10th Feb 20217:00 amRNSJohn Ma joins Smith+Nephew's Board as NED
3rd Feb 20215:00 pmRNSDirector/PDMR Shareholding
1st Feb 20211:41 pmRNSBlock listing Interim Review
1st Feb 202112:30 pmRNSTotal Voting Rights
29th Jan 20217:00 amRNSNotice of Results
28th Jan 20219:15 amRNSDirector Declaration
14th Jan 202111:30 amRNSDirector/PDMR Shareholding
11th Jan 20217:00 amRNSTrading Statement
6th Jan 20211:00 pmRNSDirectorate Change
4th Jan 20215:46 pmRNSSmith+Nephew Completes Orthopaedics Acquisition
4th Jan 202111:00 amRNSTotal Voting Rights
22nd Dec 20209:00 amRNSDirector/PDMR Shareholding
1st Dec 202012:40 pmRNSTotal Voting Rights
24th Nov 20203:30 pmRNSDirector/PDMR Shareholding
16th Nov 20203:30 pmRNSDirector/PDMR Shareholding
10th Nov 20207:00 amRNSDirector/PDMR Shareholding
10th Nov 20207:00 amRNSTotal Voting Rights
3rd Nov 202010:00 amRNSDirector/PDMR Shareholding
2nd Nov 20205:04 pmRNSDirector/PDMR Shareholding
2nd Nov 20202:45 pmRNSTotal Voting Rights
29th Oct 20203:05 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSTrading Statement
20th Oct 202010:00 amRNSKatarzyna Mazur-Hofsaess joins Smith+Nephew as NED
15th Oct 202011:52 amRNSDividend Declaration
9th Oct 20209:08 amRNSNotice of Results
8th Oct 20207:00 amRNSSmith+Nephew Prices USD Bond Issue
1st Oct 202011:08 amRNSTotal Voting Rights
1st Oct 20207:00 amRNSTrading Statement
29th Sep 20201:04 pmRNSExtremities Acquisition
15th Sep 20204:56 pmRNSDirector/PDMR Shareholding
10th Sep 202010:26 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.